FDA granted Priority Review to oral telotristat etiprate for the treatment of carcinoid syndrome. The agency has set a target action date of Nov. 30. Telotristat etiprateis sponsored by Lexicon Pharmaceuticals Inc. Telotristat etiprate targets tryptophan hydroxylase, an enzyme that triggers the excess serotonin production within mNET cells that leads to carcinoid syndrome. Telotristat etiprate...
The Biden administration has left NIH in a weakened state, intensifying politicization of science on Capitol Hill and eroding the bipartisan support the government’s premier biomedical research agency has traditionally enjoyed.
